¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Integration Host Factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® host ÇÑ±Û ¼÷ÁÖ
¼³¸í   
  ´Ù¸¥ »ý¹°(±â»ýü)À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇϴ µ¿¹° ¶Ç´Â ½Ä¹°. ¸¶Áö¸·ÀÇ ¼öÁÖ¸¦ Á¾¼÷ÁÖ, ¹ßÀ°ÀÇ µµÁß¿¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£ ¼÷ÁÖ¶ó°í ÇÑ´Ù. ±â»ýµ¿¹° Áß¿¡´Â ¼÷ÁÖ°¡ Æ¯Á¤ÇÑ Á¾ÀÏ ¶§µµ ÀÖ°í ¶Ç ¸¹Àº ±â»ýÃæ°ú °°À̱נ¹ß»ý´Ü°è¿¡ µû¶ó ¸¹Àº Á¾·ùÀÇ ¼÷ÁÖ¸¦ ÇÊ¿ä·Î Çϴ °Íµµ ÀÖ´Ù. ÀÌ °æ¿ì ¾Ö¹ú·¹°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ Áß°£¼÷ÁÖ, ¼ºÃ¼°¡ ±â»ýÇϴ ¼÷ÁÖ¸¦ ÃÖÁ¾¼÷ÁÖ¶ó°í ÇÑ´Ù. °£ÁúÀΠ°æ¿ì¿¡´Â ¹°°íµ¿ÀÌ Áß°£¼÷ÁÖÀ̰í, ¼Ò-¾ç µîÀº ÃÖÁ¾¼÷ÁÖ°¡ µÈ´Ù. ±â»ý½Ä¹°¿¡´Â °Ü¿ì»ìÀ̿͠°°ÀÌ Á¹Âü³ª¹« µîÀ» ¼÷ÁַΠÇÏ¿© ½º½º·Î ±¤ÇÕ¼ºÀ» Çϸ鼭µµ ¼÷ÁÖ¿¡°Ô¼­ ¿µ¾çÀ» ¾ò´Â °Í°ú, ¾ß°í¿Í °°ÀÌ »ý°­ µîÀÇ »Ñ¸®¸¦ ¼÷ÁַΠÇÏ¿© ¼÷ÁÖ¿¡°Ô¼­¸¸ ¿µ¾çÀ» ÀÇÁ¸Çϴ °ÍÀÌ ÀÖ´Ù. ±â»ý»ý¹°¿¡´Â ÀÌ ¹Û¿¡µµ »ý¹°ÀÇ »çü³ª ±× ºÐÇØÁß¿¡ Àִ °Í, ¹èÃâ¹° µîÀ» ¼÷ÁַΠÇϴ °Íµµ ÀÖ´Ù.
¿µ¹® graft versus host reaction ÇÑ±Û ÀÌ½ÄÆí´ë ¼÷ÁÖ¹ÝÀÀ
¼³¸í   
  ¸é¿ªÀ̶õ ÀÚ½ÅÀÇ °Í°ú ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» ±¸ºÐÇØ¼­ ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» °ø°ÝÇÏ¿© »ý¹°ÇÐÀû È°¼ºÀ» ¾ø¾Ö°Å³ª Á¦°ÅÇϴ °ÍÀÌ´Ù. ÀÌ ¸é¿ªÀº ÁַΠÇ÷¾×¿¡ Àִ ¼¼Æ÷¿¡ ÀÇÇØ¼­ ÀÌ·ç¾îÁø´Ù. Æ¯È÷ ¸²ÇÁ±¸´Â ÀÌ ¸é¿ª¿¡ ÁßÃßÀûÀΠ¿ªÇÒÀ» Çϴ ¼¼Æ÷ÀÌ´Ù. ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀÀ̶ó´Â °ÍÀº À̽ĵǾî¿Â Á¶Á÷¿¡ Á¸ÀçÇϴ ŸÀÎÀÇ Ç÷±¸µéÀÌ ¼÷ÁÖÀÇ ¼¼Æ÷¸¦ °ø°ÝÇϴ °ÍÀ» ¸»ÇÑ´Ù. Áï À̽ĵǾî¿Â Á¶Á÷°ú ÇÔ²² µé¾î¿Â Ç÷±¸µéÀÌ À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¼¼Æ÷¸¦ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÇϴ Çö»óÀÌ´Ù. À̰ÍÀº À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¸é¿ª»óŰ¡ Á¤»óÀûÀÏ °æ¿ì¿¡´Â ÀϾÁö ¾Ê´Âµ¥ ¿Ö³ÄÇϸ頸鿪»óŰ¡ Á¤»óÀÏ °æ¿ì¿¡´Â À̽ĵǾî¿Â Àå±â¿Í ´õºÒ¾î µé¾î¿Â Å¸ÀÎÀÇ Ç÷±¸µéÀ» À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ Ç÷±¸°¡ Å¸ÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼­ °ø°ÝÀ» ÇÏ°í ¼ýÀûÀ¸·Î À¯¸®ÇÏ¿© ¸ðµÎ Á×ÀÏ ¼ö°¡ Àֱ⠶§¹®ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host integration factor
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • chemical integration
    È­ÇÐÀûÅëÇÕ
  • integration
    ÅëÇÕ, À¶ÇÕ
  • memoric integration
    ±â¾ïÅëÇÕ
  • social integration
    »çȸÀûÅëÇÕ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • final host
    Á¾¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ
  • host attribute
    ¼÷ÁÖ¼Ó¼º
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host preference
    ¼÷ÁÖ¼±È£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • integration
    ÅëÇÕ
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host
    ¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host integration factor
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • chemical integration
    È­ÇÐÀûÅëÇÕ
  • integration dosimetry
    ÅëÇÕ¼±·®ÃøÁ¤
  • integration
    ÅëÇÕ
  • memoric integration
    ±â¾ïÅëÇÕ
  • primary integration
    ¼Ò¾ÆÀÏÂ÷¼ºÀÚ±âÀνÄ
  • social integration
    »çȸÀûÅëÇÕ
  • abnormal host
    ºñÁ¤»ó¼÷ÁÖ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • alternate host
    ±³´ë¼÷ÁÖ
  • amplifier host
    ÁõÆø¼÷ÁÖ
  • host adaptation
    ¼÷ÁÖÀûÀÀ
  • host attribute
    ¼÷ÁÖ¼Ó¼º
  • compromised host
    ŸÇù¼÷ÁÖ
  • crustacean host
    °©°¢·ù¼÷ÁÖ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • graphical integration
    µµ½ÄÀûºÐ(ËÀËàËøËÓ).
  • primary integration
    ¼Ò¾ÆÀÏÂ÷¼º ÀÚ±âÀνÄ(á³ä®ìéó­àõí»ÐùìããÛ).
  • Insulin-like growth factors
    Àν¶¸°¾ç(å×)¼ºÀå(à÷íþ)È£¸£¸ó
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • host
    ¼÷ÁÖ
  • host
    ¼÷ÁÖ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host integration factor (HIF)
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(èâì×àõ é©áÈ).
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(¡­é©áÈ).
  • factors
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • risk factors
  • tissue growth factors
  • chemical integration
    È­ÇÐÀû ÀûºÐ<ÀÛ¿ë>, È­ÇÐÀû ÅëÇÕ.
  • developmental test of visual motor integration
    ½Ã°¢¿îµ¿ÅëÇÕ(ãÊÊÆê¡ÔÑ÷Öùê)¹ß´Þ°Ë»ç(Û¡Ó¹ËþÞÛ)
  • graphical integration
    µµ½ÄÀûºÐ(ËÀËàËøËÓ).
  • integration
    ÅëÇÕ
  • integration
    ÅëÇÕ(÷Öùê).³»°úÀûºÐ(îÝÝÂ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Host
    ¼÷ÁÖ
    [¿¾ ¿ë¾î] ¼÷ÁÖ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • accidental host
    ¿ì¿¬¼÷ÁÖ
  • alternate host
    ±³´ë¼÷ÁÖ
  • amplifier host
    ÁõÆø¼÷ÁÖ
  • crustacean host
    °©°¢·ù¼÷ÁÖ
  • definitive host
    Á¾¼÷ÁÖ
  • first intermediate host
    Á¦ÀÏÁß°£¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host parasite relationship
    ¼÷ÁÖ±â»ýÃæ°ü°è
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • host-parasite specificity
    ¼÷ÁÖ±â»ýÃæÆ¯À̼º
  • intermediate host
    Áß°£¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • suppressor factors
    ¾ï¾Ð(ÀÚ) ÀÎÀÚ(åääâ(í­)ì×í­)
  • integration
    ÅëÇÕ(÷Öùê)
  • integration efficiency
    ÅëÇÕ È¿À²(÷Öùêüù×Ë)
  • prophage integration
    ÇÁ·ÎÆäÀÌÁö ÅëÇÕ(÷Öùê)
  • cloning host
    Ŭ·Î´× ¼÷ÁÖ(âÖñ«)
  • host
    ¼÷ÁÖ(âÖñ«)
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
  • host-controlled modification
    ¼÷ÁÖÁ¦¾î ¼ö½Ä(âÖñ«ð¤åÙáóãÞ)
  • host-controlled restriction
    ¼÷ÁÖÁ¦¾î Á¦ÇÑ(âÖñ«ð¤åÙð¤ùÚ)
  • host-guest system
    ÁÖ-°´(ñ«-ËÔ) ½Ã½ºÅÛ
  • host-induced modification
    ¼÷ÁÖÀ¯µµ ¼ö½Ä(âÖñ«ë¯ÓôáóãÞ)
  • host range
    ¼÷ÁÖ ¹üÀ§(âÖñ«ÛôêÌ)
  • host-range mutant
    ¼÷ÁÖ¹üÀ§ º¯ÀÌÁÖ(âÖñ«ÛôêÌܨì¶ñ»)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • quality factors
    Ư¼º¿ä¼Ò, Áú¿ä¼Ò
  • host
    ¼÷ÁÖ, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
  • host computer
    ÁÖÄÄÇ»ÅÍ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IHF Industrial Health Foundation; integration host factor; International Hospital Foundation
ANF Atrial Natriuretic Factors
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
NCF Neutrophilic Chemotatic Factors
CDSRF chronic disease and sociodemographic risk factors
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IHF Integration Host Factor
CIQ Community Integration Questionnaire
PIC pre-integration complex
REMI Restriction Enzyme Mediated Integration
VMI Visual Motor Integration
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • controlling factors in facial growth
    ¾È¸é ¼ºÀåÀÇ Á¶Àý ¿äÀÎ
  • host
    ¼÷ÁÖ, °³Ã¼, ¼ö¿ëÀÚ, ÇÇÀ̽Äü
    1. ¼÷ÁÖ-´Ù¸¥ »ý¹°À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇÏ´Â µ¿¹° ¶Ç´Â ½Ä¹°. 2. ÇÇÀ̽Äü, ¼ö¿ëÀÚ-´Ù¸¥ »ý¹°·ÎºÎÅÍ ±â°ü ¶Ç´Â Á¶Á÷ÀÇ À̽ÄÀ» ¹Þ´Â ¼ö¿ëÀÚ.
  • host-parasitite relationship
    ¼÷ÁÖ-±â»ýüÀÇ »óÈ£ °ü°è
  • pneumonia,in immunocompromised host
    ¸é¿ª ±â´É ÀúÇÏ ¼÷ÁÖÀÇ
  • developmental test of visual motor integration
    ½Ã°¢ ¿îµ¿ ÅëÇÕ ¹ß´Þ °Ë»ç
  • integration
    ÅëÇÕ, ÀûºÐ
    µ¿ÀÏ ¸ñÇ¥¸¦ ÇâÇÏ¿© Çùµ¿ÀûÀ¸·Î ÀÏÇÏ´Â °¢Á¾ ÀÛ¿ëÀÇ ÁýÇÕ.
  • tissue integration
    Á¶Á÷ À¶ÇÕ
    ¼­·Î ´Ù¸¥ Á¶Á÷°£¿¡ ¼­·Î À¶ÇÕÇÏ´Â °Í.
  • variable of integration
    ÀûºÐ º¯¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
virus integration Insertion of viral DNA into host-cell DNA. This includes integration of phage DNA into bacterial DNA (lysogeny) to form a prophage or integration of retroviral DNA into cellular DNA to form a provirus.
(12 Dec 1998)
personality integration The effective organization of old and new experience, data, and emotional capacities into the personality; the harmonious organization of the personality.
(05 Mar 2000)
systems integration The procedures involved in combining separately developed modules, components, or subsystems so that they work together as a complete system.
(12 Dec 1998)
integration <molecular biology, virology> Incorporation of the genetic material of a virus in to the host genome.
(18 Nov 1997)
accidental host One that harbors an organism which usually does not infect it.
(05 Mar 2000)
amplifier host A host in which infectious agents multiply rapidly to high levels, providing an important source of infection for vectors in vector-borne diseases.
(05 Mar 2000)
parasite-host ecosystem Complex of all parasite species and individuals associated with a specific host.
Synonym: parasite-host ecosystem.
Origin: parasite + G. Koinos, common, together
(05 Mar 2000)
paratenic host An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's.
Synonym: transport host.
(05 Mar 2000)
reservoir host The host of an infection in which the infectious agent multiplies and/or develops, and upon which the agent is dependent for survival in nature; the host essential for the maintenance of the infection during times when active transmission is not occurring.
(05 Mar 2000)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
cutaneous graft versus host reaction An acute erythematous maculopapular reaction with bulla formation in the most severe cases; chronic changes may resemble lichen planus or scleroderma.
(05 Mar 2000)
secondary host <epidemiology> See vector.
(05 Dec 1998)
host An organism that is infected with or is fed upon by a parasitic or pathogenic organism (for example, a virus, nematode, fungus). The term can also be applied, loosely, to a plant supporting an epiphyte.
(09 Oct 1997)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Integration Host Factors - »õâ Bacterial proteins that are used by BACTERIOPHAGES to incorporate their DNA into the DNA of the "host" bacteria. They are DNA-binding proteins that function in genetic recombination as well as in transcriptional and translational regulation.
    Synonyms : Host Factor, Host Factor Protein, Host Factors, Integration Host Factor alpha Subunit, Integration Host Factor beta Subunit, Factors, Integration Host, Host Factors, Integration
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • integration
    ÅëÇÕ
  • conglomerate integration
    (±â¾÷ÀÇ)´Ù°¢Àû ÅëÇÕ
  • horizontal integration
    ¼öÆòÀû ÅëÇÕ(µ¿ÀÏ ¾÷Á¾°£ÀÇ ÅëÇÕ)
  • integration
    (ºÎºÐ,¿ä¼ÒÀÇ)ÅëÇÕ;¿Ï¼º;Áý¼º;(ÀΰÝÀÇ)ÅëÇÕ;À¶ÇÕ;(¼ö)ÀûºÐ¹ý(cf.DIFFERENTIATION)ÀÎÁ¾ÀûÂ÷º°ÀÇ ÆóÁö
  • largescale integration
    °í¹Ðµµ Á÷Á¢È¸·Î
  • racial integration
    ÀÎÁ¾ Â÷º° ÆóÁö
  • a host of
    -ÀÌ ¸¹Àº
  • host
    ÁÖÀÎ; ±ºÁß; ¹«¸®
  • definitive host
    (»ý)Á¾°á(°íÀ¯)¼÷ÁÖ
  • host
    (¼Õ´Ô¿¡ ´ëÇÏ¿©) ÁÖÀÎ;(¿©°üÀÇ) (³²ÀÚ) ÁÖÀÎ;(±â»ý »ý¹°ÀÇ) ¼÷ÁÖ;reckon(count) without one's ~ Á¦¸Ú´ë·Î Ä¡ºÎ(ÆÇ´Ü)ÇÏ´Ù
  • host
    ¸¹Àº ¶¼;´Ù¼ö;±º¼¼;heavenly ~s;~(s) of heaven ÇÏ´ÃÀÇ º°;õ»çÀÇ ¶¼
  • host city
    (°æ±â µîÀÇ)°³ÃÖ µµ½Ã
  • host computer
    (´Ü¸»±â,¸¶ÀÌÅ©·Î ÄÄÇ»Å͸¦ °Å´À¸°)È£½ºÆ® ÄÄÇ»ÅÍ;´ë¿ë·® ÄÄÇ»ÅÍ
  • host plant
    ±âÁÖ ½Ä¹°
  • intermediate host
    Áß°£¼÷ÁÖ(±â»ýÃæÀÇ À¯»ý±âÀÇ ¼÷ÁÖ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á